Wednesday, April 24, 2019
UroGen Pharma Ltd., a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a therapeutic area of mutual interest. UroGen and Janssen will each conduct certain activities under the terms of the agreement.
“We are excited to enter into this agreement with Janssen, an industry leader with a history of developing transformative therapies,” said Liz Barrett, President and Chief Executive Officer of UroGen. “We maintain a strong commitment to bringing innovative treatments to patients in areas of unmet need.”
